Patients who use blood pressure monitors at home and use Web reporting tools that connect them to clinicians appear to significantly improve their ability to manage their hypertension, says research from Kaiser Permanente Colorado.

The study involved 348 patients with uncontrolled blood pressure who were randomly categorized into two groups: usual care and home monitoring.

The usual care group was managed in a typical model that involved checking blood pressure during office visits.

The home monitoring group used a blood pressure device that uploaded data to the patient’s account using Microsoft HealthVault, a secure, Web-based data storage site. The readings were automatically transferred to Kaiser’s electronic disease registry.

The insurer’s clinical pharmacists used the computer registry to monitor readings and consulted with patients to adjust their antihypertensive medications based on proven protocols.

“Our study suggests that using technology to engage individuals in their care at home may be a better way to help patients achieve a healthy blood pressure,” says David Magid, MD, a Kaiser senior scientist.

At the beginning of the study, the average systolic blood pressure for the home monitoring group was 149 mmHg; it was 145 mmHg in the usual care group.

At six months, patients in the home monitoring group were 50 percent more likely to have healthy blood pressure than the usual care group. Similarly, a significantly greater decrease in systolic blood pressure (–21 mmHg) at six months occurred in the home monitoring group. It was –9 mmHg for the usual care group .

In previous research, Magid found that when patients used home monitoring, and were required to write down and call in the results, progress toward the blood pressure goal was slight.

This latest study provides an additional layer of automation and convenience by directly feeding the readings from the home blood pressure cuff to the patient’s care team.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.